培美曲塞联合长春瑞滨对比长春瑞滨单药治疗转移性乳腺癌(KCSG-BR15-17):一项随机、开放标签、多中心、II期试验
这项在韩国17个中心开展的随机开放标签II期试验纳入125例既往接受过蒽环类和紫杉类治疗的转移性乳腺癌患者,1:1随机接受培美曲塞联合长春瑞滨或长春瑞滨单药治疗。联合组中位无进展生存期显著延长(5.7个月 vs 1.5个月,p<0.001),疾病控制率更高(76.8% vs 45.9%,p=0.001),总生存有延长趋势(16.8个月 vs 10.5个月,p=0.102)。
要点
- 培美曲塞联合长春瑞滨较长春瑞滨单药显著延长中位无进展生存期(5.7个月 vs 1.5个月,p<0.001)。
- 联合组疾病控制率显著高于单药组(76.8% vs 45.9%,p=0.001)。
- 联合组总生存有延长趋势但未达统计学显著(16.8个月 vs 10.5个月,p=0.102)。
核心结论
- 这项II期研究显示培美曲塞联合长春瑞滨较长春瑞滨单药延长了无进展生存期,联合方案的不良事件总体可控。
研究设计与样本
- 随机、开放标签、多中心II期试验,在韩国17个中心开展,2017年3月至2019年8月共入组125例既往接受过蒽环类和紫杉类治疗的晚期乳腺癌患者。
- 患者按1:1随机分配接受长春瑞滨单药或培美曲塞联合长春瑞滨治疗,随机化按既往卡培他滨治疗和激素受体状态分层。
- 主要终点为研究者评估的无进展生存期,次要终点包括客观缓解率、总生存、安全性和生活质量。
主要发现
- 中位随访14.1个月,共发生118例进展事件和88例死亡事件。
- 培美曲塞联合长春瑞滨组62例,长春瑞滨单药组63例。
- 培美曲塞联合长春瑞滨较长春瑞滨单药显著延长无进展生存期(5.7个月 vs 1.5个月,p<0.001)。
- 联合组疾病控制率高于单药组(76.8% vs 45.9%,p=0.001),总生存有延长趋势(16.8个月 vs 10.5个月,p=0.102)。
- 按周期计算,联合组贫血发生率高于单药组(7.9% vs 1.9%,p<0.001),3-4级中性粒细胞减少发生率两组无差异(14.7% vs 19.5%,p=0.066)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Metastatic breast cancer refractory to anthracycline and taxanes often shows rapid progression. The development of effective and tolerable combination regimens for these patients is needed. This phase II trial investigated the efficacy of pemetrexed plus vinorelbine in patients with metastatic breast cancer. METHODS: This randomized, open-label, phase II trial was conducted in 17 centers in Korea. Patients with advanced breast cancer who had previously been treated with anthracyclines and taxanes were randomly assigned in a 1:1 ratio to receive either vinorelbine or pemetrexed plus vinorelbine. Randomization was stratified by prior capecitabine treatment and hormone receptor status. The primary endpoint was investigator-assessed progression-free survival (PFS). Secondary endpoints included the objective response rate, overall survival, safety, and quality of life. RESULTS: Between March 2017 and August 2019, a total of 125 patients were enrolled. After a median follow-up duration of 14.1 months, 118 progression events and 88 death events had occurred. Sixty-two patients were assigned to the pemetrexed plus vinorelbine arm, and 63 were assigned to the vinorelbine arm. Pemetrexed plus vinorelbine significantly prolonged PFS compared to vinorelbine (5.7 vs. 1.5 months, p < 0.001). The combination arm had higher disease control rate (76.8% vs. 45.9%, p = 0.001) and a tendency toward longer overall survival (16.8 vs. 10.5 months, p = 0.102). Anemia was more frequent in the pemetrexed plus vinorelbine arm per cycle compared with vinorelbine (7.9% vs. 1.9%, p < 0.001), but there was no difference in the incidence of grade 3-4 neutropenia per cycle between the pemetrexed plus vinorelbine arm and the vinorelbine single arm (14.7% vs. 19.5%, p = 0.066). CONCLUSIONS: This phase II study showed that pemetrexed plus vinorelbine led to a longer PFS than vinorelbine. Adverse events of pemetrexed plus vinorelbine were generally manageable.
引用
- Lee DW, Jung KH, Lee KH, et al. Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial. Eur J Cancer. 2023. PMID: 38104354. doi:10.1016/j.ejca.2023.113456
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。